Zim Laboratories passes all resolutions at 42nd AGM

Zim Laboratories Limited successfully concluded its 42nd Annual General Meeting on June 29, 2026, with shareholders approving all proposed resolutions. The meeting, conducted via video conferencing, saw the adoption of the audited financial statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Zulfiquar Kamal as a director. Additionally, the members ratified the remuneration payable to cost auditors and approved a special resolution for managing director and whole-time director remuneration in case of profit inadequacy.

The proceedings were overseen by Chairman & Managing Director Dr. Anwar Siraj Daud. The Board of Directors appointed Roshni Jethani, Company Secretary in Practice, as the scrutinizer to oversee the electronic voting process. The remote e-voting period was open from June 26 to June 28, 2026, and the e-voting system remained available for 15 minutes post the conclusion of the AGM.

Voting Results

All four resolutions tabled at the meeting received approval from more than 99.99% of the valid votes cast. The detailed voting patterns for the resolutions are summarized below:

Resolution Description	Votes For	Votes Against	% For	% Against
Adoption of Financial Statements FY26	2,53,89,635	123	99.9995	0.0005
Re-appointment of Mr. Zulfiquar Kamal	2,53,89,585	173	99.9993	0.0007
Ratification of Cost Auditor Remuneration	2,53,89,585	173	99.9993	0.0007
Director Remuneration (Special Resolution)	2,53,89,635	123	99.9995	0.0005

Key Attendees and Proceedings

The meeting commenced at 11:30 a.m. IST and concluded at 1:23 p.m. Key attendees included Whole Time Directors Mr. Zulfiquar Kamal, Mr. Niraj Dhadiwal, and Mr. Prakash Sapkal, along with Independent Directors Mrs. Kavita Loya, Mr. Padmakar Joshi, Dr. Kamlesh Shende, and Mr. Ashok Bhatia. Mr. Shyam Mohan Patro, Chief Financial Officer, and Mr. Piyush Nikhade, Company Secretary, were also present.

The Chairman addressed the gathering on the company's performance during FY26 and outlined the future growth strategy. The Company Secretary confirmed that there were no qualifications or adverse remarks in the reports submitted by the Statutory Auditors and Secretarial Auditors. The statutory requirements for disclosing the proceedings under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been fulfilled.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.99%	-8.74%	+0.50%	+66.62%	-2.05%	+1.33%

Zim Laboratories Limited disclosed an inter-se transfer of 80,000 equity shares between promoters, representing 0.15% of the paid-up equity share capital. Dr. Anwar Daud acquired the shares from Mr. Zulfiqar Kamal at a price of ₹107.50 per share. The transaction was executed on or after June 11, 2026, and qualifies for an exemption from making an open offer under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The acquisition increased Dr. Anwar Daud's shareholding in the company to 25.05%, comprising 1,34,16,320 shares. Conversely, Mr. Zulfiqar Kamal's holding reduced to 2.08%, equating to 11,15,260 shares post-transaction. The transfer was conducted among the promoters of the company.

The required disclosure regarding the proposed acquisition was filed with the stock exchanges on June 4, 2026, in compliance with Regulation 10(5) of the SEBI SAST Regulations. The shares of Zim Laboratories Limited are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.